Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26963167 | 1.00 | CA12 (0.36) | CA12CA1CA9PREPAPLNR | |
| SCHEMBL28697821 | 0.82 | CA12 (0.39) | CA12CA1CA9PREPAPLNR | |
| SCHEMBL23190370 | 0.80 | CA12 (0.40) | CA12CA1CA9PREPAPLNR | |
| SCHEMBL22275369 | 0.79 | CA12 (0.36) | CA12CA1CA9PREPTSHR | |
| SCHEMBL565612 | 0.79 | CA12 (0.36) | CA12CA1CA9PREPAPLNR | |
| SCHEMBL30079871 | 0.79 | CA12 (0.36) | CA12CA1CA9PREPTSHR | |
| SCHEMBL28422272 | 0.77 | CA12 (0.46) | CA12CA1CA9PREPAPLNR | |
| SCHEMBL12492971 | 0.77 | CA12 (0.46) | CA12CA1CA9PREPAPLNR | |
| SCHEMBL17318153 | 0.74 | CA12 (0.47) | CA12CA1CA9PREP | |
| SCHEMBL319347 | 0.74 | CA12 (0.41) | CA12CA1CA9PREPAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064946-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2025-02-27 | — | — | US | disclosed |
| CN-116848120-A | Quinazoline compounds for inducing G12D mutant KRAS proteolysis | 安斯泰来制药株式会社 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023119677-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022173032-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D-MUTATION KRAS PROTEIN | アステラス製薬株式会社 | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064946-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | CA12 2114/4885CA1 1474/4885CA9 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.